Vitamin A dimer formation

Vitamin A dimer formation refers to the nonenzymatic dimerization of vitamin A derivatives, notably retinaldehyde, via Schiff base intermediates. This process produces toxic compounds such as A2E that accumulate in lipofuscin granules within the retinal pigment epithelium (RPE). These toxic dimers induce cellular dysfunction, inflammation, and contribute to retinal degenerative diseases such as Stargardt disease and age-related macular degeneration. Strategies to reduce vitamin A dimerization in the eye are being pursued as a means to slow or prevent these diseases without impairing normal visual processes[1][2][3][4][6]. This is not a canonical therapeutic target such as a receptor, enzyme, transporter, or gene product, but a pathological chemical process. The most studied toxic vitamin A dimer is A2E, which is both a biomarker and a causative agent in retinal toxicity and degeneration[3][6]. Gildeuretinol is an experimental drug designed to prevent the formation of these toxic dimers, specifically to address retinal degenerative diseases[4]. Inhibiting dimer formation pharmacologically (e.g., via deuterated vitamin A) has been shown to reduce retinal degeneration in preclinical models without affecting core vitamin A function[1][2][4].

Other names

Vitamin A dimerizationtoxic vitamin A dimer accumulationA2E formation

Inhibition of vitamin A dimerization by isotopic substitution (e.g., C20-D₃-vitamin A inhibits dimerization and lipofuscin formation)